Back to search results

RECHARGE Trial: Comparing Heart Procedures for Coronary Artery Disease in Minorities

This study, called RECHARGE: Minorities, is for people with coronary artery disease (blocked heart arteries) who identify as a minority. It compares two ways to restore blood flow to the heart: coronary artery bypass grafting (CABG), which is open-heart surgery, and percutaneous coronary intervention (PCI), a non-surgical procedure using a balloon and stent. Doctors will decide if either procedure is equally suitable for you. The study aims to see which treatment leads to better survival and quality of life over 5 years. We are looking to enroll 600 participants, but the current recruitment status is unclear.

Study design
This is a randomized, open-label study where participants are randomly assigned to one of two treatment groups. It aims to enroll 600 participants.
What's involved
You would have follow-up phone calls at 30 days, 3, 6, 12, 18, 24, 30, and 36 months, then yearly for up to 10 years. You will also have a repeat echocardiogram and blood tests at 1 year.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 5 to 10 years after their treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06399705

REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Minorities

Recruiting
PHASE3Ages 18+InterventionalPrevention
Weill Medical College of Cornell University
~600 participants
Updated 2025-10-01 on ClinicalTrials.gov
What's tested:Coronary artery bypass graftingPercutaneous coronary intervention

At a glance

Recruiting sites
18 of 18 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Hierarchical composite of all-cause death and time-averaged change from baseline in generic quality of life using the SF-12v2
Measured over 5 years

Conditions

Coronary Artery Disease

Explore related trials

Coronary Artery Disease

Where it's being run

18 sites across 11 states
New York6
Kentucky2
Tennessee2
California1
Georgia1
Indiana1
Massachusetts1
New Jersey1

Study leadership

  • Mario Gaudino, MD, PhD, MSCE, FEBCTS, FACC · PRINCIPAL_INVESTIGATOR · Weill Medical College of Cornell University
  • Gregg Stone, MD, FACC, MSCAI · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine at Mount Sinai

Who to contact

Mario Gaudino, MD, PhD, MSCE, FEBCTS, FACC
[email protected]
[email protected]
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Hierarchical composite of all-cause death and time-averaged change from baseline in generic quality of life using the SF-12v25 years

    Generic quality of life (QOL) will be assessed by utilizing the 12-item Short Form Survey (SF-12v2). The score ranges from 1-100, with higher scores indicating a better health status. The win ratio will be used